BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
2.120
-0.190 (-8.23%)
At close: Mar 28, 2025, 4:00 PM
2.090
-0.030 (-1.42%)
After-hours: Mar 28, 2025, 7:57 PM EDT

Company Description

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.

Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer’s disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia.

In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia.

BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BioXcel Therapeutics, Inc.
BioXcel Therapeutics logo
Country United States
Founded 2017
IPO Date Mar 8, 2018
Industry Biotechnology
Sector Healthcare
Employees 74
CEO Vimal Mehta

Contact Details

Address:
555 Long Wharf Drive, 12th Floor
New Haven, Connecticut 06511
United States
Phone 475 238 6837
Website bioxceltherapeutics.com

Stock Details

Ticker Symbol BTAI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001720893
CUSIP Number 09075P105
ISIN Number US09075P1057
Employer ID 82-1386754
SIC Code 2834

Key Executives

Name Position
Dr. Vimal D. Mehta Ph.D. Founder, Chief Executive Officer, President, and Director
Javier Rodriguez J.D. Senior Vice President, Chief Legal Officer and Corporate Secretary
Richard I. Steinhart MBA Senior Vice President and Chief Financial Officer
Dr. Frank D. Yocca Ph.D. Senior Vice President and Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 28, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report
Mar 21, 2025 8-K Current Report
Mar 21, 2025 8-K Current Report
Mar 4, 2025 8-K Current Report
Mar 4, 2025 424B5 Filing
Mar 3, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G Filing
Feb 6, 2025 8-K Current Report
Jan 29, 2025 8-K Current Report